Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Clinical trial NCT02670616 · COMPLETED
Trial details
- NCT number
- NCT02670616
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-01
- Primary completion
- 2020-06-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.